On Thursday, the 20th of July, the high-school life science laboratory in Ohlsbach, Germany received a FLUOstar® Omega microplate reader donated by BMG LABTECH. The device enables the young scientists to expand their research capabilities.
BMG LABTECH announces that the company has received grant for the U.S. Patent 9,733,124, entitled “Microplate Reader with Linear Variable Filter”. The patent’s claims cover a revolutionary new type of dual monochromator technology using Linear Variable Filters (LVF) for the selection of wavelength and bandwidths. The patent provides protection for this unique LVF MonochromatorTM design and recognition of the high quality of the innovation being carried out by the BMG LABTECH team.
BMG LABTECH developed a new gas ramping function that can fully manipulate the environment within a microplate reader, by mimicking in vitro hypoxia and ischaemia/reperfusion. Equipped with this unique feature, the CLARIOstar® with Atmospheric Control Unit (ACU) is the first plate reader that is able to rapidly return to physiological gas conditions upon active modification of oxygen (02) and carbon dioxide (CO2) tensions within the reader, reproducing disease-specific settings in live cell-based assays. The use of conditions that resemble as close as possible physiological or pathological conditions results in more reliable in vitro data that better translate to in vivo situations.
Next Generation Sequencing (NGS) has become a powerful tool to investigate genetic changes that lead to cancer or diseases. DNA quantification is essential for NGS, where precise amounts of DNA are required. With its highly sensitive microplate readers, BMG LABTECH helps to accurately quantify DNA and ensure the required precision. The versatile multi-mode microplate readers are equipped with an ultrafast UV/vis spectrometer for fast quality and quantity determinations as well as unique technologies for high throughput fluorescence DNA quantification.
Three European technology SME’s, Luxcel Biosciences Ltd, Axiogenesis AG and BMG LABTECH GmbH, together with two internationally recognised research institutions, Oxford University and Imperial College London, have been awarded €2.5m funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development.